Scleral buckling or PPV can treat rhegmatogenous RD in BD

Article

Scleral buckling or pars plana vitrectomy (PPV) can be used to treat rhegmatogenous retinal detachment (RD) associated with Beh?et's disease (BD), according to researchers in the Department of Ophthalmology, Zagazig University, Egypt.

Scleral buckling or pars plana vitrectomy (PPV) can be used to treat rhegmatogenous retinal detachment (RD) associated with Behçet's disease (BD), according to researchers in the Department of Ophthalmology, Zagazig University, Egypt.

The researchers retrospectively reviewed the medical records of all patients at their institution who had undergone surgical intervention for rhegmatogenous RD associated with BD between June 2007 and June 2012. They reported their results in BMC Ophthalmology.

The study included 7 eyes of 7 patients. Five eyes were treated with scleral buckling (4 segmental buckle and 1 encircling buckle); 2 eyes were treated with PPV. One eye initially treated by scleral buckling showed recurrence of RD and was subsequently treated with PPV. All 7 retinas were successfully reattached at the end of a follow-up period of 22.0 (± 6.7) months.

"Rhegmatogenous RD is a rare posterior segment complication of BD but it should be kept in mind, especially if the patient presented with marked diminution of vision on top of the chronic course of the disease, and careful examination should be considered especially in cases with media opacity," the researchers wrote. "Segmental scleral buckle or PPV are effective and safe in management of this complication in BD patients with no unusual complications."

The researchers added that 3 of the patients had a history of receiving an intravitreal injection of triamcinolone acetonide to treat attacks of panuveitis or resistant cystoid macular oedema, and in all cases their RD occurred within 8 weeks of the injection. This led them to speculate that intravitreal injection of triamcinolone acetonide may be a precipitating factor for the development of rhegmatogenous RD, and they urged close observation of such patients after injection.

To read the entire article, go to the journal's website.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.